[1]马若璇,冉振龙,张月玲,等.玻璃体内注射康柏西普对糖尿病性黄斑水肿患者黄斑区视网膜血管密度和中心凹无血管区面积的影响[J].眼科新进展,2020,40(4):365-368.[doi:10.13389/j.cnki.rao.2020.0084]
　MA Ruoxuan,RAN Zhenlong,ZHANG Yueling,et al.Effect of intravitreal injection of Conbercept for treatment of diabetic macular edema on retinal vessel density at macular region and foveal avascular zone area[J].Recent Advances in Ophthalmology,2020,40(4):365-368.[doi:10.13389/j.cnki.rao.2020.0084]
点击复制

玻璃体内注射康柏西普对糖尿病性黄斑水肿患者黄斑区视网膜血管密度和中心凹无血管区面积的影响/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
40卷
期数:
2020年4期
页码:
365-368
栏目:
应用研究
出版日期:
2020-04-05

文章信息/Info

Title:
Effect of intravitreal injection of Conbercept for treatment of diabetic macular edema on retinal vessel density at macular region and foveal avascular zone area
作者:
马若璇; 冉振龙; 张月玲; 顾朝辉
067000　河北省承德市，承德医学院研究生学院（马若璇）；071000　河北省保定市，保定市第一中心医院眼二科（冉振龙，张月玲，顾朝辉）
Author(s):
MA Ruoxuan1; RAN Zhenlong2; ZHANG Yueling2; GU Zhaohui2
1.Graduate school of Chengde Medical College，Chengde 067000，Hebei Province，China
2.Department of Ophthalmology，Baoding First Central Hospital，Baoding 071000， Hebei Province，China
关键词:
糖尿病性黄斑水肿; 康柏西普; 光学相干断层扫描血管成像; 中心凹无血管区面积; 血管密度
Keywords:
diabetic macular edema;  Conbercept;  optical coherence tomography angiography;  foveal avascular zone;  vessel density
分类号:
R774
DOI:
10.13389/j.cnki.rao.2020.0084
文献标志码:
A
摘要:
目的　探讨玻璃体内注射抗血管内皮生长因子（vascular endothelial growth factor，VEGF）药物康柏西普治疗糖尿病性黄斑水肿（diabetic macular edema ,DME）患者对黄斑区视网膜微循环的影响。方法　应用光学相干断层扫描血管成像（optical coherence tomography angiography,OCTA）观察36例DME患者，在接受连续3个月每月1次玻璃体内注射0.5 mg 康柏西普治疗前后最佳矫正视力（BCVA）、中心视网膜厚度（central retinal thickness,CRT）及黄斑区浅层和深层视网膜毛细血管的血管密度（vessel density，VD）和中心凹无血管区（foveal avascular zone，FAZ）面积的变化。结果　DME患者康柏西普玻璃体内注射治疗前BCVA为0.26±0.02，3次注射治疗后BCVA分别为0.42±0.04、0.51±0.04及0.54±0.04，治疗后BCVA较治疗前显著提高；治疗前CRT为（472.42±9.68）μm，3次注射治疗后CRT分别为（339.33±6.73）μm、（320.89±7.60）μm、（300.14±5.60）μm，治疗后CRT较治疗前显著降低，BCVA及CRT治疗前后差异均有统计学意义（均为P＜0.05）。DME患者治疗前浅层视网膜毛细血管VD为（44.27±0.04）%，3次注射治疗后分别为（44.28±0.04）%、（44.32±0.04）%、（44.32±0.04）%;治疗前的深层视网膜毛细血管VD为（52.96±0.04）%，3次注射治疗后分别为（52.94±0.04）%、（52.87±0.04）%、（52.87±0.04）%;治疗前浅层FAZ面积为（0.56±0.08）mm2，3次注射治疗后分别为（0.56±0.08）mm2、（0.56±0.08）mm2及（0.56±0.08）mm2;治疗前深层FAZ面积为（0.75±0.10）mm2，3次注射治疗后分别为（0.75±0.09）mm2、（0.75±0.09）mm2及（0.75±0.09）mm2，治疗后患者浅层及深层视网膜毛细血管VD和FAZ面积与治疗前比较，差异均无统计学意义（均为P>0.05）。结论　DME患者连续3个月每月1次玻璃体内注射0.5 mg康柏西普治疗，能有效提高患者的BCVA，降低其CRT，并对视网膜毛细血管VD及FAZ面积无显著影响。
Abstract:
Objective　To investigate the effect of the intravitreal injection of anti-vascular endothelial growth factor (VEGF) Conbercept for treatment of diabetic macular edema (DME) on macular retinal microcirculation.Methods　The changes of best corrected visual acuity (BCVA), central retinal thickness (CRT), vessel density (VD) and foveal avascular zone (FAZ) area in the superficial and deep retinal capillary of 36 DME patients were observed by optical coherence tomography angiography (OCTA) before and after intravitreal injection of 0.5 mg Conbercept once a month for 3 consecutive months.Results　BCVA was 0.26±0.02 for DME patients before receiving anti-VEGF treatment, and 0.42±0.04, 0.51±0.04 and 0.54±0.04 after three times of injection, respectively. BCVA after treatment was significantly higher than that before treatment. CRT was (472.42±9.68) μm before treatment, and (339.33±6.73) μm, (320.89±7.60) μm and (300.14±5.60) μm after 3 times of treatment. CRT after treatment was significantly lower than that before treatment. No statistical differences were observed in BCVA and CRT between before and after treatment (both P< 0.05). VD in the superficial retinal capillary was (44.27±0.04)% for DME patients before treatment, (44.28±0.04)%, (44.32±0.04)% and (44.32±0.04)% after 3 times of treatment; VD in the deep retinal capillary was (52.96±0.04)%, (52.94±0.04)%, (52.87±0.04)% and (52.87±0.04)% after 3 times of treatment. FAZ at superficial layer was (0.56±0.08) mm2 before treatment, (0.56±0.08) mm2, (0.56±0.08) mm2 and (0.56±0.08) mm2 after 3 times of treatment. FAZ at deep layer was (0.75±0.10) mm2 before treatment, and (0.75±0.09) mm2, (0.75±0.09) mm2 and (0.75±0.09) mm2 after 3 times of treatment. No statistical differences were observed in VD and FAZ areas at superficial layer and deep layer between before and after treatment (all P>0.05).Conclusion　Intravitreal injection of 0.5 mg Conbercept once a month for 3 months can effectively improve BCVA and reduce CRT of DME patients, and have no significant effect on VD and FAZ area of retinal capillaries.

参考文献/References:

［1］　SIMO R，HERNANDEZ C.Intravitreous anti-VEGF for diabetic retinopathy:hopes and fears for a new therapeutic strategy ［J］.Diabetologia,2008,51(9):1574-1580.
［2］　NGUYEN Q D，BROWN D M，MARCUS D M，BOYER D S,PATEL S,FEINER L，et al.Ranibizumab for diabetic macular edema:results from 2 phase III randomized trials:RISE and RIDE ［J］.Ophthalmology，2012，119(4):789-801.
［3］　MASSIN P，BANDELLO F，GARWEG J G，HANSEN L L，HARDING S P，LARSEN M，et al.Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study):a 12-month，randomized，controlled，double-masked，multicenter phase II study［J］.Diabetes Care，2010，33(11):2399-2405.
［4］　MANOUSERIDIS K，TALIKS J.Macular ischaemia:a contraindication for anti-VEGF treatment in retinal vascular disease［J］.Br J Ophthalmol，2012,96(2):179-184.
［5］　TERUI T，KONDO M，SUGITA T，ITO Y，KONDO N，OTA I，et al.Changes in areas of capillary nonperfusion after intravitreal injection of bevacizumab in eyes with branch retinal vein occlusion［J］.Retina，2011，31(6):1068-1074.
［6］　CAMPOCHIARO P A，WYKOFF C C，SHAPIRO H，RUBIO R G，EHRLICH J S.Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema［J］.Ophthalmology，2014，121(9):1783-1789.
［7］　SOPHIE R，HAFIZ G，SCOTT A W，ZIMMER-GALLER I，NGUYEN Q D，YING H.Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion:the role of progression of retinal nonperfusion［J］.Am J Ophthalmol，2013，156(4):693-705.
［8］　中华医学会眼科学会眼底病学组.我国糖尿病视网膜病变临床诊疗指南(2014年)［J］.中华眼科杂志，2014，50（11）：851-865.
FUNDUS DISEASES GROUP OF OPHTHALMOLOGY SOCIETY OF CHINESE MEDICAL ASSOCIATION.Guidelines for clinical diagnosis and treatment of diabetic retinopathy in China (2014) ［J］.Chin J Ophthalmol，2014,50(11):851-865.
［9］　HARTIG S M .Basic image analysis and manipulation in image［J］.Curr Protoc Mol Biol，2013,102:141510-141512.
［10］　DAS A，MCGRIRE P G，RANGASAMY S .Diabetic Macular Edema:Pathophysiology and Novel Therapeutic Targets［J］.Ophthalmology，2015，122(7):1375-1394.
［11］　SHIMURA M，YASUDA K.Macular ischaemia after intravitreal bevacizumab injection in patients with central retinal vein occlusion and a history of diabetes and vascular disease［J］.Br J Ophthalmol，2010，94(3):381-383.
［12］　LEUNG L S，SILVA R A，BLUMENKRANZ M S，FLYNN H W Jr,SANISLO S R.Macular infarction following intravitreal bevacizumab for treatment of central retinal vein occlusion［J］.Ophthalmic Surg Lasers Imaging，2012,43:E73-E79.
［13］　HWANG T S，GAO S S，LIU L，LAUER A K，BAILEY S T，FLAXEL C J，et al.Automated quantification of capillary nonperfusion using optical coherence tomography angiography in diabetic retinopathy［J］.JAMA Ophthalmol，2016,134(4):367-373.
［14］　SIM D A，KEANE P A，ZARRANZ-VENTURA J，BUNCE C V，FRUTTIGER M，PATEL P J,et al.Predictive factors for the progression of diabetic macular ischemia［J］.Am J Ophthalmol，2013,156(4):684-692.

相似文献/References:

[1]麻南 李丹 高付林 胡莲娜.玻璃体内注射贝伐单抗和贝伐单抗/曲安奈德联合用药治疗糖尿病性黄斑水肿疗效及安全性差异的荟萃分析[J].眼科新进展,2012,32(6):000.
[2]王玲,生侠,吴清静,等.红外线及自发荧光影像在糖尿病性黄斑水肿诊断中的价值[J].眼科新进展,2014,34(8):754.[doi:10.13389/j.cnki.rao.2014.0207]
　WANG Ling,SHENG Xia,WU Qing-Jing,et al.Value of infrared ray and auto fluorescence in diagnosis of diabetic macular edema[J].Recent Advances in Ophthalmology,2014,34(4):754.[doi:10.13389/j.cnki.rao.2014.0207]
[3]杨宇,田敏,吕红彬. 糖尿病视网膜病变的治疗进展[J].眼科新进展,2015,35(5):497.[doi:10.13389/j.cnki.rao.2015.0136]
　YANG Yu,TIAN Min,LV Hong-Bin. Recent advances in treatment of diabetic retinopathy[J].Recent Advances in Ophthalmology,2015,35(4):497.[doi:10.13389/j.cnki.rao.2015.0136]
[4]李素华,高永峰. 比较单独黄斑局灶/格栅样光凝术和联合雷珠单抗治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2015,35(6):566.[doi:10.13389/j.cnki.rao.2015.0153]
　LI Su-Hua,GAO Yong-Feng. Efficacy of macular focal / grid photocoagulation combined with ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):566.[doi:10.13389/j.cnki.rao.2015.0153]
[5]夏风杰,闫峰,陆燕,等.糖尿病性黄斑水肿临床治疗进展[J].眼科新进展,2015,35(10):985.[doi:10.13389/j.cnki.rao.2015.0270]
　XIA Feng-Jie,YAN Feng,LU Yan,et al.Clinical treatment advances in diabetic macular edema[J].Recent Advances in Ophthalmology,2015,35(4):985.[doi:10.13389/j.cnki.rao.2015.0270]
[6]张娣,张玲,杨静,等.玻璃体内注射康柏西普联合手术及全视网膜光凝治疗新生血管性青光眼[J].眼科新进展,2015,35(12):1170.[doi:10.13389/j.cnki.rao.2015.0320]
　ZHANG Di,ZHANG Ling,YANG Jing,et al.Intravitreal injection of conbercept combined with operation and panretinal photocoagulation for neovascular glaucoma[J].Recent Advances in Ophthalmology,2015,35(4):1170.[doi:10.13389/j.cnki.rao.2015.0320]
[7]李秀云,朱艳,邓爱军.Ranibizumab治疗糖尿病性黄斑水肿短期疗效观察[J].眼科新进展,2016,36(1):067.[doi:10.13389/j.cnki.rao.2016.0019]
　LI Xiu-Yun,ZHU Yan,DENG Ai-Jun.Short-term efficacy of Ranibizumab for diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(4):067.[doi:10.13389/j.cnki.rao.2016.0019]
[8]陈素芳,李亨辉,邵毅,等.非诺贝特在糖尿病性黄斑水肿中的临床研究[J].眼科新进展,2016,36(2):136.[doi:10.13389/j.cnki.rao.2016.0037]
　CHEN Su-Fang,LI Heng-Hui,SHAO Yi,et al.Clinical study of fenofibrate in diabetic macular edema[J].Recent Advances in Ophthalmology,2016,36(4):136.[doi:10.13389/j.cnki.rao.2016.0037]
[9]李娜,张杰,高荣玉,等.单次注射康柏西普治疗渗出型AMD患者RPE隆起面积与容积变化[J].眼科新进展,2016,36(2):172.[doi:10.13389/j.cnki.rao.2016.0047]
　LI Na,ZHANG Jie,GAO Rong-Yu,et al.Changes of retinal pigment epithelium uplift area and volume in exudative age-related macular degeneration after once injection of conbercept[J].Recent Advances in Ophthalmology,2016,36(4):172.[doi:10.13389/j.cnki.rao.2016.0047]
[10]王琛,李东豪,闻毅颐.玻璃体内注射康柏西普联合周边视网膜选择性光凝治疗视网膜静脉阻塞继发黄斑水肿的疗效及安全性[J].眼科新进展,2016,36(5):471.[doi:10.13389/j.cnki.rao.2016.0126]
　WANG Chen,LI Dong-Hao,WEN Yi-Yi.Intravitreal injection of conbercept combined with selective peripheral retinal photocoagulation for macular edema secondary to retinal vein occlusion[J].Recent Advances in Ophthalmology,2016,36(4):471.[doi:10.13389/j.cnki.rao.2016.0126]
[11]宋志刚,魏少华.577 nm激光光凝联合玻璃体内注射康柏西普治疗糖尿病性黄斑水肿的效果观察[J].眼科新进展,2019,39(4):373.[doi:10.13389/j.cnki.rao.2019.0085]
　SONG Zhi-Gang,WEI Shao-Hua.Effect of 577 nm laser photocoagulation combined with intravitreal injection of conbercept on diabetic macular edema[J].Recent Advances in Ophthalmology,2019,39(4):373.[doi:10.13389/j.cnki.rao.2019.0085]
[12]冉振龙,张海江,陈强,等.康柏西普联合黄斑格栅光凝治疗糖尿病性黄斑水肿的疗效[J].眼科新进展,2020,40(9):845.[doi:10.13389/j.cnki.rao.2020.0192]
　RAN Zhenlong,ZHANG Haijiang,CHEN Qiang,et al.The effect of conbercept combined with macular grid photocoagulation on diabetic macular edema[J].Recent Advances in Ophthalmology,2020,40(4):845.[doi:10.13389/j.cnki.rao.2020.0192]
[13]宋泽娟,徐静,李婵.羟苯磺酸钙联合康柏西普治疗糖尿病性黄斑水肿的疗效和安全性[J].眼科新进展,2021,41(1):075.[doi:10.13389/j.cnki.rao.2021.0016]
　SONG Zejuan,XU Jing,LI Chan.Clinical efficacy and safety of calcium dobesilate combined with conbercept in the treatment of diabetic macular edema[J].Recent Advances in Ophthalmology,2021,41(4):075.[doi:10.13389/j.cnki.rao.2021.0016]
[14]邓爱萍,田润,熊成,等.地塞米松玻璃体内植入剂早期联合康柏西普在抗血管内皮生长因子治疗反应不佳糖尿病性黄斑水肿中的应用[J].眼科新进展,2023,43(9):722.[doi:10.13389/j.cnki.rao.2023.0145]
　DENG Aiping,TIAN Run,XIONG Cheng,et al.Application of intravitreal dexamethasone implant combined with Conbercept in the treatment of diabetic macular edema with poor response to anti-vascular endothelial growth factor therapy[J].Recent Advances in Ophthalmology,2023,43(4):722.[doi:10.13389/j.cnki.rao.2023.0145]

备注/Memo

备注/Memo:
N/A
更新日期/Last Update: 2020-04-05